Key Takeaway
Run a full baseline panel before your first injection. Retest targeted markers at 6 to 8 weeks, a full panel at 3 to 4 months, then repeat every 6 to 12 months. Different peptides need different timing. IGF-1 on GH peptides moves slowly, while MK-677 can shift insulin inside 2 weeks.
Most people who run peptides skip the follow-up labs. Thats how small problems, rising fasting insulin, a climbing IGF-1, a cortisol shift, turn into real ones. The schedule below fixes that without forcing you to test every month or spend thousands of dollars.
The four checkpoints are baseline, early response, stabilization, and maintenance. Each one has a purpose, and each one catches a different class of change.
What is the four-stage peptide testing schedule?
The four-stage schedule is baseline before your first dose, early response at 6 to 8 weeks, stabilization at 3 to 4 months, then maintenance every 6 to 12 months. This rhythm catches problems early without overspending on labs.
Baseline sets your personal reference range. Without it, you cant tell whether a 150 ng/mL IGF-1 reading is low for you or normal for you. Early response labs, drawn at 6 to 8 weeks, check that the peptide is working and that the most likely side effects havent shown up. A growth hormone secretagogue that hasnt moved IGF-1 by week 8 is either underdosed, fake, or not absorbing.
Stabilization labs at 3 to 4 months confirm the full hormonal and metabolic picture. By this point, steady-state levels are locked in and your body has adapted. Maintenance testing every 6 to 12 months catches slow drift, especially with long-term GH peptide use where IGF-1 can creep up over years.
For the full baseline workup, see our complete panel before starting peptides guide. It lists every marker worth drawing on day zero.
When should you retest by peptide type?
Each peptide class has its own retest window because they change different markers at different speeds. GH peptides shift IGF-1 over 4 to 6 weeks. MK-677 can push insulin up inside 2 weeks. Kisspeptin moves LH within days. BPC-157 rarely shifts labs at all.
The table below covers the common peptide classes and when to draw follow-up labs. Doses and timing assume standard adult use with clinical oversight.
| Peptide | First retest | Markers | Ongoing cadence |
|---|---|---|---|
| Sermorelin, CJC-1295, ipamorelin | 6 weeks | IGF-1, fasting glucose | 3 months, then every 6 months |
| MK-677 (ibutamoren) | 4 weeks | Fasting insulin, glucose, HbA1c | Cortisol at 8 weeks, full panel at 3 months |
| Kisspeptin, gonadorelin | 2 to 4 weeks | LH, FSH, total T, estradiol | 3 months, then every 6 months |
| Tesamorelin | 3 months | IGF-1, lipids, visceral fat imaging | Every 6 months |
| Semaglutide, tirzepatide | 3 months | HbA1c, lipids, kidney function | Every 6 months |
| BPC-157, TB-500 | Symptom-based | Minimal labs; CBC if symptomatic | Annual |
| 5-amino-1MQ | 6 to 8 weeks | Metabolic panel, lipids | Every 6 months |
| NAD+ peptides | Baseline only | Methylation panel baseline | Annual if continued |
GH peptides need close IGF-1 watching because thats the marker that tracks exposure. Our IGF-1 testing guide walks through how to read the numbers and what counts as a red flag.
For kisspeptin and gonadorelin, youre tracking the HPG axis, so pull a full hormone panel that covers testosterone and estradiol at each checkpoint.
Why does timing matter more than frequency?
Timing matters more than frequency because peptides hit different markers at different speeds, and a poorly timed draw gives you a useless number. Test too early and you havent reached steady state. Test too late and you miss the early adverse shift that would have let you dose-correct.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for physician-supervised GLP-1 therapy.
Try the BMI Calculator →IGF-1 is the clearest example. Sermorelin or CJC-1295 pushes IGF-1 upward by stimulating pituitary GH release, but IGF-1 is a liver-produced metabolite of GH. The half-life is long, production is steady, and the marker takes about 4 to 6 weeks to reach a new equilibrium. Draw it at week 2 and the number wont have moved yet. You might assume the peptide is dead when its working fine.
MK-677 is the opposite problem. It raises GH and IGF-1, but it also drives insulin and blood glucose up fast. Fasting insulin can climb inside 2 weeks. If you wait 3 months to check it, youve been insulin resistant for 11 weeks without knowing. A 4-week insulin check catches that while its still reversible with a dose cut.
Kisspeptin works on a minutes-to-days timescale for LH and FSH pulsatility. A draw at 2 to 4 weeks tells you whether the HPG axis is responding. Waiting 3 months is too long for course correction.
How much should you budget for proper lab monitoring?
Budget $600 to $1,200 per year for a single peptide with proper monitoring. Direct-to-consumer panels run $100 to $400 each depending on breadth. A realistic year is one $300 baseline, one $150 targeted retest at 6 weeks, one $300 full panel at 3 months, then one $300 annual.
Costs climb if youre stacking. GH peptides plus semaglutide plus a sleep aid like MK-677 means you need IGF-1, insulin, HbA1c, lipids, kidney function, and liver enzymes. Thats a full metabolic plus hormone panel at every checkpoint, not a targeted pull.
The cheapest way to stay compliant is to batch. Draw everything at the same visit and use a direct-to-consumer lab like Quest or LabCorp through a service that offers bundled panels. See how to order peptide labs without a doctor for pricing and ordering flow.
Skipping labs to save $600 a year is a bad trade. One missed insulin rise on MK-677 can cost you 6 months of metabolic correction. One undetected IGF-1 climb on CJC-1295 can push you into the zone where long-term cancer risk concerns apply.
What should you do when results shift?
Your response depends on the size of the shift. A mild move within the reference range means recheck in 4 weeks. A moderate shift outside your baseline but still in range means dose reduction plus a recheck at 4 to 8 weeks. A major shift outside the reference range or a symptom cluster means stop the peptide and retest at 4 to 8 weeks.
Mild shift example: IGF-1 climbs from 180 to 220 ng/mL on CJC-1295, still inside the age-adjusted reference range. Hold dose, recheck at 4 weeks, see if it stabilizes or keeps rising.
Moderate shift example: fasting insulin rises from 6 to 14 on MK-677 but HbA1c is still 5.3. Cut the dose in half, recheck insulin and glucose at 4 weeks. If insulin drops back under 10, stay at the reduced dose.
Major shift example: IGF-1 at 380 ng/mL on sermorelin (above range for most adults), or HbA1c jumping from 5.2 to 6.0 on MK-677. Stop the peptide. Retest at 4 to 8 weeks to confirm the marker is trending back toward baseline. Do not resume without a clinical review.
Symptoms override numbers. Swollen hands, carpal tunnel pain, persistent water retention, or new headaches on GH peptides mean stop regardless of what IGF-1 says.
What are the red flags that mean stop immediately?
Stop the peptide the same day if you see any of these: IGF-1 above the adult reference range, fasting insulin above 20 with rising HbA1c, new edema in hands or feet, carpal tunnel symptoms, persistent headaches, unexplained heart palpitations, or visual changes. These are not wait-and-see findings.
IGF-1 above range on GH peptides means your pituitary is being pushed past physiological levels. Long-term elevated IGF-1 is associated with increased risk of certain cancers and cardiovascular events. The marker is the early warning. Ignoring it is the mistake.
Persistent fasting insulin above 20 on MK-677, especially with an HbA1c creeping toward 6, means you are developing insulin resistance. Thats a treatable problem if you catch it at week 4. At week 12 its harder to reverse.
New edema, carpal tunnel pain, or joint stiffness on any GH secretagogue means the dose is too high. These are the same symptoms seen in acromegaly, and they mean your tissues are holding fluid from supraphysiological GH exposure.
Palpitations, chest pressure, or visual changes on any peptide are emergencies. Stop immediately and see a clinician. Browse verified clinicians in the directory or start a consult if you need help interpreting results.
Frequently asked questions
Do I really need a baseline panel before starting a peptide?
Yes. Without baseline numbers, a follow-up IGF-1 of 220 ng/mL tells you nothing. It could be your normal, or it could be a 50% climb from 145. The baseline is cheap insurance and it lets every future lab mean something.
Can I skip the 6-week retest if I feel fine?
Not with MK-677, GH peptides, or anything that affects the HPG axis. You can feel great with fasting insulin at 22 or IGF-1 at 380. Symptoms lag labs. Thats the whole point of the 6 to 8 week draw.
How long does IGF-1 take to return to baseline after stopping a GH peptide?
About 2 to 4 weeks for most people. The peptide itself clears in hours, but IGF-1 is a downstream liver product that reflects GH exposure over time. Retest at 4 weeks off-cycle to confirm youre back at or below your baseline number.
Do I need labs on BPC-157?
Minimal labs. BPC-157 doesnt reliably shift standard markers. Baseline CBC and CMP are reasonable, then monitor symptoms. If you develop unexplained fatigue, bruising, or persistent GI issues, run a CBC and CMP to rule out a rare response.
Whats the difference between a targeted retest and a full panel?
A targeted retest pulls 2 to 4 markers tied to the specific peptide: IGF-1 for GH peptides, fasting insulin and glucose for MK-677, LH and FSH for kisspeptin. A full panel adds CBC, CMP, lipids, thyroid, and hormones. Targeted is for 6-week checkpoints. Full is for 3-month and annual.
Can I use a home finger-stick kit for peptide monitoring?
For HbA1c and fasting glucose, yes. For IGF-1, fasting insulin, and hormone panels, no. Those require venous draws and proper handling. Mixing home finger-stick with venous lab panels is fine for the markers each method handles well.
How do I know if my peptide is underdosed or fake?
The 6-week retest is the answer. If IGF-1 hasnt moved at all after 6 weeks of a GH peptide at a standard dose, the product is either underdosed, degraded, or counterfeit. Real CJC-1295 at 100 mcg daily reliably pushes IGF-1 up by 50 to 100 ng/mL.
Should I retest more often if Im stacking multiple peptides?
Yes. Stacking increases the number of markers at risk and the speed of change. Run the 6-week targeted panel for each peptide separately at its appropriate window, then a combined full panel at 3 months. Stacked use usually costs $200 to $400 more per year in labs.
Medical disclaimer: This article is for educational purposes only and is not medical advice. Always consult your healthcare provider before starting any medication. Individual results vary. FormBlends is a licensed telehealth platform; nothing here replaces a personal clinical evaluation. Last reviewed 2026-04-17.